Perspective Therapeutics, INC 8-K filings

Perspective Therapeutics announced Q2 2026 financial results, detailing progress in its radiopharmaceutical pipeline, including VMT-NET and VMT01 programs, and maintaining a cash runway into late 2027.

Perspective Therapeutics, Inc. has updated its corporate presentation, detailing advancements in its next-generation radiopharmaceutical oncology treatments, including VMT--NET, VMT01, and PSV359.

Perspective Therapeutics, Inc. has updated its corporate presentation, detailing advancements in its radiopharmaceutical oncology portfolio, including data on VMT--NET and VMT01 trials.

Perspective Therapeutics, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of directors and ratification of its independent auditor.

Perspective Therapeutics announced its first-quarter 2026 financial results, highlighting progress in its radiopharmaceutical programs and a strengthened financial position with cash runway into late 2027.

Perspective Therapeutics, Inc. shared preliminary financial data and an update on its clinical programs and manufacturing technologies at an analyst event.

Perspective Therapeutics announced updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT--NET, showing continued tolerability and encouraging anti-tumor activity in neuroendocrine tumor patients.

Perspective Therapeutics announced its full year 2025 financial results and provided updates on its lead radiopharmaceutical programs, including positive clinical data and a recent $164 million equity offering.

Perspective Therapeutics announced the successful pricing and closing of an underwritten public offering, raising approximately $175 million in gross proceeds to fund clinical development and manufacturing.

Perspective Therapeutics, Inc. updated its corporate presentation, highlighting promising early clinical data for its next-generation radiopharmaceutical oncology programs.

Perspective Therapeutics updates its corporate presentation, highlighting progress in next-generation radiopharmaceutical oncology treatments.

Perspective Therapeutics announced positive interim clinical data for its lead VMT-NET program and outlined strategic priorities for its radiopharmaceutical pipeline.

Perspective Therapeutics announced updated interim data from its Phase 1/2a clinical trial of [212Pb]VMT--NET for neuroendocrine tumors, showing continued tolerability and durable disease control.

Perspective Therapeutics, Inc. updated its corporate presentation, highlighting its radiopharmaceutical therapy pipeline, upcoming data milestones, and clinical trial progress for neuroendocrine tumors and metastatic melanoma.

Perspective Therapeutics announced its third-quarter 2025 financial results and provided updates on its radiopharmaceutical clinical programs, including positive interim data for [212Pb]VMT-NET.

Perspective Therapeutics, Inc. updated its corporate presentation, highlighting advancements in its radiopharmaceutical pipeline, robust manufacturing, and a strong financial position extending into late 2026.

Perspective Therapeutics, Inc. updated employment agreements for its CEO, CAO, and CMO, revising compensation and change-in-control severance terms.

Perspective Therapeutics announced updated positive interim results from its Phase 1/2a clinical trial of [212Pb]VMT--NET for neuroendocrine tumors, demonstrating strong anti-tumor activity and excellent tolerability.

Perspective Therapeutics, Inc. updated its corporate presentation, highlighting its innovative radiopharmaceutical platform and promising early clinical trial data for neuroendocrine tumors and metastatic melanoma.

Perspective Therapeutics announced the appointment of Joel Sendek, a seasoned biotech finance executive and Wall Street analyst, as its new Chief Financial Officer, effective September 4, 2025.

Perspective Therapeutics, a radiopharmaceutical company, has appointed Maya Martinez-Davis, a seasoned pharmaceutical executive, as an independent director to its Board of Directors.

Perspective Therapeutics, Inc. updated its corporate presentation, highlighting its radiopharmaceutical therapy platform and clinical pipeline for neuroendocrine tumors and melanoma.

Perspective Therapeutics announced its second quarter 2025 financial results and provided updates on its clinical programs, including positive interim data for [212Pb]VMT--NET and progress in other trials.

Perspective Therapeutics, Inc. updated its corporate presentation, emphasizing its radiopharmaceutical therapy platform and ongoing clinical trials for neuroendocrine tumors and melanoma.

Perspective Therapeutics, Inc. updated its corporate presentation on July 3, 2025, showcasing its robust radiopharmaceutical platform, promising clinical trial results for its lead programs in neuroendocrine tumors and melanoma, and a strong financial position with funding into late 2026.

Perspective Therapeutics has received U.S. FDA alignment to advance its Phase 1/2a clinical trial for [212Pb]VMT-NET in neuroendocrine tumors to a higher dose Cohort 3, while also presenting positive dosimetry and safety data at SNMMI 2025.

Perspective Therapeutics, Inc. filed an 8-K announcing an updated corporate presentation, showcasing its advanced radiopharmaceutical therapy platform and positive early clinical data for neuroendocrine tumors and melanoma.

Perspective Therapeutics, Inc. announced updated interim results from its Phase 1/2a clinical trial of [212Pb]VMT--NET for neuroendocrine tumors, highlighting a favorable safety profile and encouraging anti-tumor activity.

Perspective Therapeutics, Inc. announced the successful election of its board of directors, ratification of its independent auditor, and advisory approval of executive compensation at its 2025 Annual Meeting of Stockholders.

Perspective Therapeutics announced its Q1 2025 financial results and provided a business update, highlighting progress in its clinical trials and manufacturing capabilities.